To the Editor: In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, Marso et al. (July 28 issue)1 found that persons with type 2 diabetes who were at high risk for cardiovascular events had lower rates of cardiovascular events with liraglutide than with placebo. Although the authors state that… (More)
There is scarce scientific information assessing participants' perception of pharmaceutical research in developed and developing countries concerning the risks, safety, and purpose of clinical trials.
To assess the perception that 604 trial participants (cases) and 604 nonparticipants (controls) of pharmaceutical clinical trials have… (More)